AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

Authors

Mark A. Socinski

Advent Health Hematology and Oncology, Orlando, FL

Mark A. Socinski , Alexander I. Spira , Luis G. Paz-Ares , Martin Reck , Shun Lu , Makoto Nishio , Jiang Li , Yunfei Zhou , Joon Whan Rhee , Sandra Chica Duque , Xinmin Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

First Author: Melissa Lynne Johnson

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.

First Author: Benjamin Besse

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

First Author: Delvys Rodriguez-Abreu